AEV
0.009
50%
KFM
0.061
-21.8%
VTA
0.021
31.3%
CMO
0.004
-20%
HIQ
0.005
25%
SRJ
0.004
-20%
VKA
0.011
22.2%
DTZ
0.026
-18.8%
WCN
0.023
21.1%
TZN
0.019
-17.4%
A8G
0.21
20%
FAU
0.01
-16.7%
MGU
0.006
20%
PL9
0.005
-16.7%
ABE
0.037
19.4%
UNT
0.005
-16.7%
JAV
0.097
18.3%
BRY
0.011
-15.4%
HMD
0.039
18.2%
CMP
0.235
-14.5%
SLA
0.13
18.2%
AGN
0.15
-14.3%
NYM
0.053
17.8%
GEN
0.006
-14.3%
EAU
0.14
16.7%
LRM
0.018
-14.3%
INF
0.007
16.7%
M4M
0.006
-14.3%
XST
0.014
16.7%
X2M
0.006
-14.3%
KLI
0.325
16.1%
SLB
0.275
-14.1%
HVY
0.4
15.9%
NOX
0.065
-13.3%
REC
0.037
15.6%
AS2
0.007
-12.5%
AHE
0.015
15.4%
AUV
0.007
-12.5%
DRX
0.016
14.3%
MRD
0.042
-12.5%
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

BOT successful completion of human factors validation study

Clinical dermatology company Botanix Pharmaceuticals (ASX:BOT) announces that the Company has successfully completed the planned human factors validation study assessing the revised Instructions for Use for Sofpironium Bromide gel https://cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research/1.0/file/2924-02753854-6A1186430 #shorts